This fixed combination drug is not indicated for initial therapy of hypertension. Hypertension requires therapy titrated to the individual patient. If the fixed combination represents the dose so determined, its use may be more convenient in patient management. The treatment of hypertension is not static, but must be re-evaluated as conditions in each patient warrant.
MINIZIDE® is a combination of MINIPRESS® (prazosin hydrochloride) plus RENESE® (polythiazide). MINIPRESS (prazosin hydrochloride), a quinazoline derivative, is the first of that chemical class of antihypertensives.
MINIZIDE is indicated in the treatment of hypertension. (See box warning.)
Media Articles Related to Minizide (Prazosin / Polythiazide)
Source: MedicineNet Fainting Specialty [2015.02.19]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 2/19/2015 12:00:00 AM
"Danger" molecule may be new therapeutic target for male hypertension
Source: Hypertension News From Medical News Today [2015.02.17]
Higher levels of a "danger" molecule may be one reason males tend to become hypertensive earlier and more severely than females, scientists say.
New Hypertension Recs Planned in 2016
Source: MedPage Today Cardiovascular [2015.02.17]
(MedPage Today) -- AHA/ACC recommendations will replace JNC schema.
Pregnancy associated hypertension linked to an increased frequency of subsequent hypertension and metabolic syndrome
Source: Hypertension News From Medical News Today [2015.02.04]
In a study to be presented on Feb. 5 in an oral concurrent session at 2:45 p.m.
New hypertension guidelines could save lives and money
Source: Hypertension News From Medical News Today [2015.01.30]
Increased treatment of severe hypertension particularly cost-effectiveFull implementation of new hypertension guidelines could prevent 56,000 cardiovascular disease events (mostly heart attacks...
Page last updated: 2015-02-19